Estandarización de un modelo murino de malaria cerebral en fases clínicas para la evaluación de terapias antimaláricas y de rescate. [artículo]
Por: Bautista, José M [Instituto de Investigación i+12]
| Díez, Amalia [Instituto de Investigación i+12] | Linares Gómez, María [Instituto de Investigación i+12] | Marín García, Patricia [Instituto de Investigación i+12] | Puyet, Antonio [Instituto de Investigación i+12].
Colaborador(es): Instituto de Investigación imas12.
Editor: Anales De La Real Academia Nacional De Farmacia, 2013Descripción: 79(2):274-92.Recursos en línea: Solicitar documento Resumen: Cerebral malaria (CM) is included among the more devastating SNC infectious diseases due to its high mortality and severe sequelae in children. Currently, no specific pharmacological treatment for CM or rescue therapy for neurocognitive residual injury are available, and research on this topic has been hampered due to the lack of well-defined experimental models. In the present study we have characterized the CM murine infection phenotypically, evaluating clinical parameters, which allowed establishing a model encompassing four distinct disease stages. This protocol provides the experimental framework to study adjunctive neuroprotective therapies that may prevent and/or eliminate the neurological sequelae in individuals surviving CM.
| Tipo de ítem | Ubicación actual | Signatura | Estado | Fecha de vencimiento |
|---|---|---|---|---|
Artículo
|
PC529 (Navegar estantería) | Disponible |
Formato Vancouver:
Martínez G, Linares M, Marín-García P, Pérez-Benavente S, Puyet A, Bautista JM et al. Estandarización de un modelo murino de malaria cerebral en fases clínicas para la evaluación de terapias antimaláricas y de rescate. An Real Acad Nac Farm. 2013;79(2):274-92.
NO PMID
Contiene 40 referencias
Cerebral malaria (CM) is included among the more devastating SNC infectious diseases due to its high mortality and severe sequelae in children. Currently, no specific pharmacological treatment for CM or rescue therapy for neurocognitive residual injury are available, and research on this topic has been hampered due to the lack of well-defined experimental models. In the present study we have characterized the CM murine infection phenotypically, evaluating clinical parameters, which allowed establishing a model encompassing four distinct disease stages. This protocol provides the experimental framework to study adjunctive neuroprotective therapies that may prevent and/or eliminate the neurological sequelae in individuals surviving CM.
No hay comentarios para este ejemplar.